Cover Image

革新追蹤概況 2016年:醫藥品開發平台的評估

Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline

出版商 CBR Pharma Insights 商品編碼 363445
出版日期 內容資訊 英文 70 Pages
Back to Top
革新追蹤概況 2016年:醫藥品開發平台的評估 Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline
出版日期: 2016年06月01日 內容資訊: 英文 70 Pages

促進從本報告提供藥物研發階段達到預註冊階段到,現在,醫藥品產業的開發平台上20,756項產品,治療領域及各適應症總括性詳細分析,醫藥品產業開發平台的目前規模結構及變遷,這10年的First-in-Class產品 (劃時代的醫藥品)的批准數量的增加要素,及開發平台的組合中企業策略等相關分析。

第1章 目錄

第2章 簡介

  • 醫藥品開發成本的增加
  • 大部分的醫藥品R&D成本的回復失敗
  • 已通過核准醫藥品的契約生命週期
  • First-in-Class醫藥品革新的案例
  • 結論

第3章 醫藥品產業開發平台的評估

  • 開發平台、臨床實驗形勢:各治療領域
  • 開發平台:各開發階段
  • 開發平台:各分子類型
  • 主要的治療領域:各適應症
    • 腫瘤學
    • 感染疾病
    • 中樞神經系統
    • 免疫學
  • 結論

第4章 醫藥品產業開發平台的革新的評估

  • First-in-Class的革新:各開發階段
  • 主要的治療領域:各適應症
    • 腫瘤學
    • 感染疾病
    • 中樞神經系統
    • 免疫學
  • 結論

第5章 企業分析

  • 結論

第6章 契約分析

  • 授權契約
  • 共同開發契約
  • M&A
  • 資本採購

第7章 附錄

Product Code: GBI067CBR


GBI Research's latest report, "Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline" is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.

A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005-2008, when the proportion was relatively high.


  • What is the current size and composition of the pharmaceutical industry pipeline and how has it changed since Q1 2015? What can we learn from this?
  • The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?
  • What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?
  • What factors have been driving the increasing number of first-in-class product approvals over recent decades?
  • What strategies have companies typically been pursuing with their pipeline portfolio, in terms of how diverse, specialized or innovative they have been? Specifically, what strategies have the top 25 pharmaceutical companies been following?
  • What key discernible trends have appeared in the strategic consolidations landscape in the past decade and which disease areas have been most active?

Key Reasons to Purchase

This report will allow you to -

  • Achieve an up-to-date understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process
  • Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one's own strategic positioning against this backdrop
  • Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications
  • Make key decisions about the role of innovation within one's own pipeline portfolio

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Increasing Cost of Drug Development
  • 2.2. Most Drugs Fail to Recuperate R&D Costs
  • 2.3. Contracting Life Cycles for Approved Products
  • 2.4. The Case for First-in-Class Pharmaceutical Innovation
  • 2.5. Conclusion

3. Assessment of the Pharmaceutical Industry Pipeline

  • 3.1. Pipeline and Clinical Trials Landscape by Therapy Area
  • 3.2. Pipeline by Stage of Development
  • 3.3. Pipeline by Molecule Type
  • 3.4. Key Therapy Areas by Indication
    • 3.4.1. Oncology
    • 3.4.2. Infectious Diseases
    • 3.4.3. Central Nervous System
    • 3.4.4. Immunology
  • 3.5. Conclusion

4. Assessment of Innovation in the Pharmaceutical Industry Pipeline

  • 4.1. First-in-Class Innovation by Stage of Development
  • 4.2. Key Therapy Areas by Indication
    • 4.2.1. Oncology
    • 4.2.2. Infectious Diseases
    • 4.2.3. Central Nervous System
    • 4.2.4. Immunology
  • 4.3. Conclusion

5. Company Analysis

  • 5.1. Conclusion

6. Deals Analysis

  • 6.1. Licensing Deals
  • 6.2. Co-development Deals
  • 6.3. Mergers and Acquisitions
  • 6.4. Capital Raising

7. Appendix

  • 7.1. References
  • 7.2. Contact Us
  • 7.3. Disclaimer
Back to Top